Lignocaine Infusion in Colorectal Cancer Patient Immune Cells (LICPIC Study) Read More

Radiological And subjective measures of Nutrition, Diet and sarcOpenia - a Masterplan Substudy (RANDOMS) Read More

This is an open-label, randomised, prospective, multi-centre registry-based trial evaluating the impact of delivering all active cytotoxic agents during initial systemic therapy, by way of an alternating treatment schedule versus standard of care, on outcomes in treatment-naïve mCRC. Read More

An organoid sensitivity testing driven umbrella study for patients with chemorefractory metastatic colorectal cancer. Read More

PALliative oEsOphageal cancer chemoradioimmunotherapy (PALEO): A multicentre Phase II Clinical Trial Read More

Neoadjuvant Immune-Chemo-Radiotherapy in operable oesophageal and gastro-oesophageal junction cancers with Carboplatin Paclitaxel Radiotherapy and Avelumab – a Trial assessing feasibility and preliminary Efficacy Read More

Can Oxaliplatin dose reduction and neurotoxicity be reduced with ibudilast in people with metastatic colorectal cancer? A phase II randomised study. Read More

mFOLFIRINOX And STEreotactic body Radiotherapy (SBRT) for Pancreatic cancer with high-risk and Locally Advanced disease (MASTERPLAN): a multicentre, randomised phase II study. Read More

Prospective Study of ‘Watch and Wait’ Strategy in Patients with Rectal Cancer who have Developed a Clinical Complete Response with concurrent Chemo‐radiotherapy: RENO trial (REctal cancer No Operation) Read More

This study aims to demonstrate that a chemotherapy decision incorporating ctDNA results in addition to standard pathologic risk assessment will reduce the number of patients receiving adjuvant chemotherapy. Read More

This study aims to demonstrate that a ctDNA informed approach to chemotherapy, following surgery for localised pancreatic cancer, could lead to a reduction in the proportion of patients with detectable ctDNA after completion of treatment compared to standard of care. Read More

The purpose of the DYNAMIC-III study is to determine that a chemotherapy decision based on the presence or absence of circulating tumour DNA after surgery for stage III colorectal cancer, will be more effective than standard of care treatment as measured by how many patients remain cancer free at 3 years. Read More

The aim of ACTICCA-1 is to determine whether treating patients with chemotherapy following surgery for cancer of the biliary tract helps to reduce cancer recurrence. Read More

The purpose of TOPGEAR is to investigate the benefit of adding radiation (chemoradiotherapy) to chemotherapy and surgery to treat and improve the overall survival in patients undergoing surgery for resectable stomach cancer. Read More

The aim of NABNEC is to determine the safety and efficacy of carboplatin plus nab-paclitaxel in comparison with the current standard chemotherapy treatment plan (carboplatin plus etoposide) for advanced gastrointestinal neuroendocrine carcinomas (NECs). Read More

The ASCOLT study will evaluate the safety and effectiveness of low-dose aspirin compared to placebo in reducing recurrence of colorectal cancer and improving survival for patients with Dukes C and high-risk Dukes B colorectal cancer. Read More

This randomised phase II trial aims to evaluate the effect of simvastatin (SIM) on efficacy and toxicity of pCRT in rectal cancer patients, and on systemic and local inflammatory responses. Read More

The aim of this study is to investigate the activity of anti-EGFR monotherapy, or combined with infusional 5FU, in a molecularly selected, elderly patient population with metastatic colorectal cancer. Read More

The purpose of INTEGRATE II is to determine whether Regorafenib is effective in prolonging survival in patients with Advanced Gastro-Oesophageal Carcinoma (AGOC). Read More